Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

CCoya Therapeutics, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
C

Coya Therapeutics, Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
    Sep 15, 2026Coya Therapeutics Press Releases
  • Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
    Sep 8, 2026Coya Therapeutics Press Releases
  • Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
    Aug 11, 2026Coya Therapeutics Press Releases
  • Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
    Jun 18, 2026Coya Therapeutics Press Releases
  • Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
    Jun 15, 2026Coya Therapeutics Press Releases
  • Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
    Jun 8, 2026Coya Therapeutics Press Releases
  • Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
    May 27, 2026Coya Therapeutics Press Releases
  • Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
    May 12, 2026Coya Therapeutics Press Releases
  • Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
    May 12, 2026Coya Therapeutics Press Releases
  • Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
    Apr 9, 2026Coya Therapeutics Press Releases
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
$4.97Close ยท Oct 9, 2026